March 24, 2020 / 12:43 PM / 14 days ago

BRIEF-Dynavax And Clover Biopharmaceuticals Announce Research Collaboration To Evaluate Coronavirus Vaccine Candidate With CPG 1018 Adjuvant

March 24 (Reuters) - Dynavax Technologies Corp:

* DYNAVAX AND CLOVER BIOPHARMACEUTICALS ANNOUNCE RESEARCH COLLABORATION TO EVALUATE CORONAVIRUS (COVID-19) VACCINE CANDIDATE WITH CPG 1018 ADJUVANT

* DYNAVAX TECHNOLOGIES CORP - CLOVER ADVANCING EVALUATION OF ITS PROTEIN-BASED CORONAVIRUS VACCINE CANDIDATE (COVID-19 S-TRIMER)

* DYNAVAX TECHNOLOGIES CORP - PROVIDING CPG 1018 TO SUPPORT RAPID DEVELOPMENT OF CLOVER’S COVID-19 VACCINE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below